Image: Robin Marty [CC BY 2.0], via Flickr
Pharmaceutical company leaders join US president in decrying impact on innovation and scientific decision-making
The United States president and pharmaceutical company leaders have criticised a court decision to freeze regulatory approval of a long-used abortion pill, saying the decision undermines the national drug regulator and threatens innovation.
US district judge Matthew Kacsmaryk ruled on 7 April to stay the US Food and Drug Administration’s 2000 approval of mifepristone, saying that the regulator had not taken sufficient account of safety issues.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.